As of Jan 17, 2025, DexCom, Inc. Intrinsic Value is $30.0. This suggests it may be overvalued by 64.4% compared to its current price of around $84.4.
As of Jan 17, 2025, DexCom, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $9.7. This suggests it may be overvalued by 88.5% to its current price of around $84.4, using a discount rate of 9.3% and terminal growth rate of 3.0%.
DexCom, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $30.0, compared to a market price of around $84.4. This suggests a potential overvaluation of 64.4%.